The CRDMO’s delisting by the U.S. Department of Defense complies with a recent U.S. District Court of Columbia order granting WuXi AppTec’s motion for preliminary injunction.
The new 220,000-square-foot facility will make active pharmaceutical ingredients and drug products that support the company’s sponsored clinical trials worldwide.
The company said it’s taking actions to offset the financial impact next year through increased demand in non-GLP-1 biologics and other high-value products.
The facilities will expand Lonza’s clinical through commercial capabilities in antibody-drug conjugates, viral vectors for cell and gene therapies, and drug delivery.
Private equity firm GI Partners acquired Charles River’s contract development and manufacturing organization business and has formed an independent company.
CEO Greg Behar contends the company is investing in the technologies, capabilities, and expertise needed to remain one of the industry’s leading CDMOs.
Jubilant HollisterStier, KBI Biopharma, and Kindeva are benchmarking XR-based biomanufacturing technician onboarding outcomes versus non-XR training protocols.
